Content Stream

First Epinephrine Auto-Injector for Infants and Small Children Will Be Available in 2018

kaléo today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for AUVI-Q® (epinephrine injection, USP) 0.1 mg, the first and only epinephrine auto-injector (EAI) specifically designed for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and small children weighing 16.5 to 33 pounds (7.5 to 15 kilograms) who are at risk for or have a history of serious allergic reactions.

Kids With Food Allergies
A Division of the Asthma and Allergy Foundation of America
4259 W Swamp Rd, Suite 408, Doylestown, PA 18902
Phone: 215.230.5394 | Fax: 215.340.7674
-->
×
×
×
×